1506TiP - Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
- Resource Type
- Abstract
- Source
- In
Annals of Oncology October 2018 29 Supplement 8 - Subject
- Language
- ISSN
- 0923-7534